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Introduction
Acute bacterial skin and skin-structure infection (ABSSSI) is a 
frequent cause of morbidity in both the community and hospital 
settings. Staphylococcus aureus is the most frequent cause of 
these infections, and methicillin-resistant S. aureus (MRSA) 
represents the first resistant pathogen involved in complicated 
forms of skin and soft-tissue infections (cSSTI) [1,2].  This review 
addresses the changing definition, classification and aetiology 
from cSSTI to ABSSSI and the clinical profile of patients with 
ABSSSI; it also evaluates recent advances in the treatment of 
this various group of conditions. In particular, we explore the 
management of MRSA infections analysing the different new 
and old therapeutic options.
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Abstract
In 2013 the US Food and Drug Administration (FDA) issued recommendations and guidance on developing drugs for treatment of skin 
infection using a new definition of acute bacterial skin and skin-structure infection (ABSSSI). The new classification includes cellulitis, 
erysipelas, major skin abscesses and wound infection with a considerable extension of skin involvement, clearly referring to a severe subset 
of skin infections. The main goal of the FDA was to better identify specific infections where the advantages of a new antibiotic could be 
precisely estimated through quantifiable parameters, such as improvement of the lesion size and of systemic signs of infection. Before the 
spread and diffusion of methicillin-resistant Staphylococcus aureus (MRSA) in skin infections, antibiotic therapy was relatively straightforward. 
Using an empiric approach, a β-lactam was the preferred therapy and cultures from patients were rarely obtained. With the emergence of 
MRSA in the community setting, initial ABSSSI management has been changed and readdressed. Dalbavancin, oritavancin and tedizolid are new 
drugs, approved or in development for ABSSSI treatment, that also proved to be efficient against MRSA. Dalbavancin and oritavancin have a 
long half-life and can be dosed less frequently. This in turn makes it possible to treat patients with ABSSSI in an outpatient setting, avoiding 
hospitalization or potentially allowing earlier discharge, without compromising efficacy. In conclusion, characteristics of long-acting antibiotics 
could represent an opportunity for the management of ABSSSI and could profoundly modify the management of these infections by reducing 
or in some cases eliminating both costs and risks of hospitalization.
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Definition and classification
The severity of SSTI is dependent on various factors, and the 
clinical spectrum ranges from mild forms to life-threatening 
variants. The definition of cSSTI identifies patients who need 
complex management including surgical procedures and antibiotic 
treatment, and/or who have significant underlying co-morbidities 
such as diabetes, systemic immunosuppression or neurological 
diseases [3,4]. This category includes both healthy individuals with 
severe infections and patients with co-morbidities and relatively 
minor infections. However, several classifications of SSTI have 
been proposed and heterogeneous syndromes, irrespective 
of the severity and the extension of the disease, have been 
categorized as cSSTI [5,6].  This terminology has been widely 
used in clinical trials, with partial benefits deriving from broad 
inclusion criteria. However, there was a lack of clear evidence to 
evaluate the patients whose conditions were improving quickly. 
Therefore, in 2013 the US Food and Drug Administration (FDA) 
issued new guidelines on developing drugs for treatment of cSSTI 
and introduced the new definition of ABSSSI, which now includes 
cellulitis, erysipelas, major skin abscesses and wound infections 
with a minimum lesion surface area of 75 cm2. Diabetic foot 
ulcers, burns and chronic wound infections are excluded from 
this new definition (see Table 1).  The main goal of the FDA was 
to better identify specific infections for which the advantages of a 
new antibiotic could be precisely estimated through quantifiable 
parameters, such as improvement of the lesion size and of 
systemic signs of infection [7].
Aetiology of ABSSSI
Globally, the most common cause of SSTI is S. aureus, which also 
includes MRSA.  Although S. aureus is the predominant pathogen, 
Streptococcus pyogenes and other streptococci, enterococci and 
Gram-negative bacteria can also be involved in ABSSSI [8–10]. 
Staphylococcus aureus is rated as the main pathogen in all 
regions across North America, Latin America and Europe [11], 
and is also the most common cause of cSSTI in Europe.  A study 
of more than 3000 cSSTI-associated isolates, sampled from 19 
countries in and around Europe during 2008–2009, found that 
almost one-third were S. aureus and, of those, approximately 
one-half were MRSA [12]. Recent epidemiological data of 
the European Antimicrobial Resistance Surveillance (EARS) 
Network from 28 participating countries suggested that, 
overall, MRSA accounted for 16.7% of all S. aureus isolates and 
rates of >25% were reported from Cyprus, Greece, Italy and 
Malta (see Fig. 1). Gram-negative aetiology is more common 
in surgical-site infections: in the SENTRY programme (1998–
2004) Pseudomonas aeruginosa was the second most important 
pathogen, followed by Escherichia coli [8].
Patients with MRSA frequently present with a previous 
history of MRSA infection, advanced age, chronic open 
wounds, underlying chronic disease and repeated contact with 
a healthcare facility (see Table 2 for a more complete list of 
risk factors) [13]. Compared with hospital-associated MRSA, 
community-acquired MRSA tends to be more virulent and may 
carry genes that encode the Panton–Valentine leucocidin, as 
well as many other exotoxins that are associated with tissue 
necrosis and a greater severity of disease [14,15]. However, 
community-acquired MRSA seems to be less problematic in 
Europe than in the USA [16,17].
Recognition of ABSSSI as a tool to measure clinical 
cure
The FDA definitions place some emphasis upon signs of 
systemic involvement or regional involvement (such as lymph 
node enlargement) as part of the initial clinical presentation. 
The current guidelines only cite fever as a systemic sign; other 
signs and symptoms include leucocytosis, and increased serum 
C-reactive protein levels, procalcitonin levels, and erythrocyte 
sedimentation rates [18]. Clinical therapeutic success is based 
on objective criteria such as reduction of the initial lesions 
and their size (length, width and area) ≥20% in the size of the 
lesion within 48–72 h plus resolution of fever (i.e. temperature 
<37.7°C at three consecutive recordings using the same 
methodology every 6 h between 48 and 72 h). Importantly, 
the timing of the primary efficacy assessment should be done 
48–72 h after the beginning of the therapy, to minimize the 
confounding influence of the immune response. Subsequently, 
the secondary end-point should be the assessment of efficacy 
after 7–14 days of therapy [19].
As aforementioned, the primary concern in ABSSSI is MRSA, 
which is the specific target of most recent antimicrobials 
studied under the new FDA guidance. It is also important to 
highlight that inadequate treatment of MRSA is an important 
risk factor for recurrent infections [20].
TABLE 1. Disease manifestations of acute bacterial skin and skin-
structure infection (ABSSSI)a
Included in the definition  
of ABSSSI
Excluded from the definition  
of ABSSSI
Cellulitis/erysipelas Impetigo and minor cutaneous abscess
Wound infections Animal or human bites
Major cutaneous abscess Necrotizing fasciitis
Diabetic foot infection
Burns
Chronic wound infection
Myonecrosis
Ecthyma gangrenosum
aLesions should have a minimum surface area of 75 cm2; erythema and/or 
induration should extend ≥5 cm from the peripheral margin of the infection; 
systemic signs of infection (such as fever) and/or proximal lymphadenopathy.
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Acknowledging these important steps, an important goal of 
management of ABSSSI should be to reduce inpatient hospital 
stay and readmissions through seamless transitions of care 
from the emergency department to hospital wards and then to 
discharge.  The final target is to optimize the healthcare system 
through appropriate management and empiric antibiotic 
treatment of ABSSSI [21].
Diagnosis of ABSSSI
Microbiological diagnosis of SSTI and in particular of ABSSSI 
is often an object of concern for physicians. Surface cultures 
of wounds usually represent colonizing microbes, which 
cannot be easily differentiated from the underlying aetiological 
agent and are not indicative of infections such as cellulitis or 
subcutaneous abscesses. In addition, the sensitivity of blood 
cultures, especially in patients with cellulitis, is low. Tissue 
biopsies after deep debridement are the most valuable tool and 
the specimen of choice is a biopsied sample of the advancing 
margin of the lesion. Pus on a surface swab is inadequate and 
does not represent the disease process. In contrast, cultures 
are indicated for the patient who presents exudates or abscess 
and requires operative incision and drainage after debridement 
and cleansing of necrotic tissues. This procedure should be 
performed considering the high risk for deep structures and 
underlying tissues. Radiological imaging is particularly important 
in patients with ABSSSI. Ultrasonography is the most common 
and easiest method for assessing the presence of abscesses and 
can be used to guide therapeutic aspiration of deeper abscesses. 
Computed tomography scans can also be used in the diagnosis 
of deeper infections, while magnetic resonance imaging can 
detect soft-tissue alterations and is the most sensitive non-
invasive method to determine the extent of tissue involvement 
and whether an infection is necrotizing [22].
Clinical profile of patients with ABSSSI
Although ABSSSI is a common cause of admission to the 
emergency department, the majority of patients can be treated 
effectively as outpatients with or without surgical intervention. 
For patients with more severe ABSSSI who actually need 
hospital admission, an effective communication and care 
transition between the emergency department and the hospital 
ward is crucial. However, an easy and well-defined clinical and 
therapeutic algorithm that evaluates the need for hospitalization, 
FIG. 1. Proportion of methicillin-resistant Staphylococcus aureus (MRSA) isolates in participating countries in 
2013.* European Antimicrobial Resistance Surveillance (EARS) Network [70]. *Reproduced with permission 
from the European Centre for Disease Prevention and Control.
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subsequent discharge and inpatient management has not been 
established. Such an algorithm should provide an appropriate 
pathway for case management while minimizing complications, 
readmissions, and inappropriate antibiotic use.
Clinical decision-making for ABSSSI in the emergency 
department is based on risk stratification [23]. For patients 
with ABSSSI who are unstable, an appropriate antimicrobial 
therapy should be started immediately.
In the majority of ABSSSI, an empiric antibiotic therapy is 
administered while in the emergency department and cultures 
are rarely collected.  The aetiology of cellulitis without a wound 
or drainage is unclear because of the difficulty of obtaining an 
adequate sample for culture. Treatment should be guided by 
recognition of the most common pathogens, which in most 
cases are Gram-positive cocci. In contrast, antibiotic therapy 
for Gram-negative bacteria is not generally indicated in the 
treatment of most cases of ABSSSI [24,25].
The assessment of lesions that require surgery is essential. 
Inadequate drainage is often a reason for the apparent failure 
of an initial outpatient antibiotic regimen. In larger and more 
indurated lesions, ultrasound may provide valuable information. 
Patients with large and deep abscesses that require extensive 
debridement may require hospitalization for operative treat-
ment and more intensive therapies.
Once a patient is admitted to the hospital, physicians play a 
key role in optimizing the choice of an appropriate antimicrobial 
regimen and evaluating the need for surgical intervention. After 
antibiotic treatment has been initiated empirically, physicians 
must follow the culture results and start a targeted antibiotic 
therapy as soon as possible. Physicians should try to reduce the 
duration of therapy and identify possibilities for an early switch 
to oral therapy or to outpatient parenteral antimicrobial therapy. 
Infectious disease specialists can provide recommendations for 
an optimal empiric and de-escalation therapy and for a switch 
to an outpatient antimicrobial therapy [26]. Oral therapy is 
recommended for patients who have had no fever for more 
than 24 h, show a normalized white blood cell count, and have 
the ability to take oral medications [27]. Once oral therapy 
is initiated, patient discharge should be planned (see Table 3). 
Typically, patients who are afebrile for at least 48 h and physically 
independent are ready to be discharged [28].
In internal medicine wards, elderly patients with high rates of 
co-morbidities are frequently hospitalized for long periods [29]. 
In this setting, an early discharge to home or other wards or 
hospitals, such as long-term care facilities, should be encouraged 
[30]. Multidisciplinary ABSSSI evaluation and management 
programmes can potentially contribute to better outcomes 
and coordination of care from the emergency department to 
the hospital (for patients requiring admission), and from the 
wards to the outpatient setting. Frequently, patients hospitalized 
with ABSSSI are prescribed an inadequate initial therapy, which 
is more common when the patient is older (>65 years) and 
presents co-morbidities, has difficulty in taking oral drugs, has 
recurrent or nosocomial infections, or has MRSA infection or 
septic shock [31,32].
On this basis, the use of an empiric antibiotic therapy tailored 
to the clinical features and risk factors of each patient might be 
the right approach for the management of ABSSSI. Moreover, an 
early switch to oral therapy or the use of long-acting antibiotics 
seems to be the best strategy to obtain an early discharge to 
home or to other facilities.
Treatment of ABSSSI and the role of new 
antibiotics
Before the spread and diffusion of MRSA in skin infections, 
empiric antibiotic therapy with a β-lactam was favoured and 
cultures were rarely obtained [33]. With the occurrence of 
MRSA in the community setting, initial ABSSSI management 
has been changed [34,35]. Three therapeutic approaches are 
favoured in treating skin infections: (a) surgical drainage and 
debridement, (b) wound culture with susceptibility testing, and 
(c) early and appropriate empiric antibiotic therapy [36]. Surgical 
drainage is recommended for abscesses or a purulent infection, 
whereas mechanical or chemical debridement is advised for 
TABLE 2. Risk factors for different bacterial skin and soft-tissue 
infections
Methicillin-resistant  
Staphylococcus aureus
Gram-negative, anaerobes  
and polymicrobial
Anamnestic factors:
Previous colonization
Contact with patients colonized
Antibiotic therapy in the previous 
12 months
Hospitalization in the previous 
12 months
History of previous infection
Recent travel in Latin America, Africa, 
South East Asia
Residence in long-term care facilities
Previous intensive care unit admission
Surgical site infections:
Axillary cavity
Gastrointestinal tract
Perineum
Female genital tract
Co-morbidities:
Cardiovascular disease
Diabetes mellitus
Peripheral vascular disease
Chronic wounds
Immunodepression
Central venous catheter
Chronic renal disease
Dialysis
Intravenous drug abuse
Co-morbidities:
Diabetes mellitus
Cirrhosis
Intravenous drug abuse
Subcutaneous drug abuse
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devitalized tissue in severe ABSSSI [37]. Wound cultures are 
highly recommended in patients with severe local infection 
and those who have failed on antibiotic treatment [38]. The 
rate of initial treatment failure may be considerably high for 
skin infections: in a study that reviewed data from more than 
100 US hospitals, 16.6% of acute infections, 34.1% of chronic 
or ulcerative infections, and 26.7% of surgical site infections 
had initial treatment failure [39]. In particular, failure to initiate 
an antimicrobial therapy active against the causative pathogen 
within 48 h has been reported as an independent risk factor 
for treatment failure [40].  This is the main reason why the FDA 
guidance for ABSSSI suggested evaluation of clinical response 
48–72 h after initiation of therapy, a tool that has proved useful 
in assessing therapeutic failure [41]. However, it is important to 
underline that Zervos et al. did not find an association between 
inappropriate therapy and outcomes, except in the subset of 
patients with ulcers [42]. Patients whose conditions deteriorate 
despite empiric antibiotic therapy should be treated more 
aggressively on the basis of Gram staining, culture and antibiotic 
susceptibility. Worsening of ABSSSI may indicate the presence 
of resistant pathogens, and therapy should be readdressed [43]. 
After initial treatment failure, MRSA should be considered as 
a possibility in hospitalized patients, and the choice of a new 
agent should be made on the basis of susceptibilities [44]. The 
need for source control, such as drainage or debridement, 
should also be carefully considered for patients not responding 
to antibiotic treatment.
Recently, the Infectious Disease Society of America developed 
new practice guidelines for the diagnosis and the management 
of SSTI [45]. SSTI were divided into two categories: purulent 
and non-purulent. Additionally, therapeutic indications were 
stratified on the basis of clinical manifestations, classified as mild, 
moderate and severe. Non-purulent infections include cellulitis 
and erysipelas, whereas abscesses fall into the purulent category. 
No differences are reported in the therapeutic approach to 
mild, moderate and severe purulent infections: cultures for 
test sensitivity, incision and drainage of the site of infection 
are considered the milestone of the treatment. Vancomycin, 
linezolid, tigecycline, daptomycin, ceftaroline and telavancin are 
considered the drugs of choice for severe infection [46,47]. 
Trimethoprim-sulfamethoxazole and doxycycline are used 
for moderate infections, and cefazolin and clindamycin are 
considered for severe infection due to methicillin-susceptible 
S. aureus. Recently, in a randomized trial on uncomplicated 
wound infection, trimethoprim-sulfamethoxazole was asso-
cia ted with a higher recurrence of infection compared with 
clindamycin [48].
Vancomycin plus piperacillin/tazobactam is the first line of 
treatment for severe non-purulent infections, especially if a 
necrotizing or polymicrobial infection is suspected. A defined 
aetiology due to Streptococcus pyogenes requires treatment with 
a penicillin plus clindamycin. For moderate and mild infections 
the choice is between a penicillin, ceftriaxone, cefazolin or 
clindamycin (see Table 4). No sufficient or definitive data 
are reported concerning the use of teicoplanin in ABSSSI 
due to MRSA. Recently, Lawson et al. reported data from a 
retrospective study to characterize real-world dosing of weight-
based intravenous antibiotic therapy in patients hospitalized for 
MRSA cSSTI [49]. The new recommended teicoplanin dose for 
patients with MRSA cSSTI is 400 mg (~6 mg/kg) every 12 h for 
three doses, followed by a daily dose of 6 mg/kg [50]. New data 
are necessary to assess the role of teicoplanin in the treatment 
of these infections.
Once culture and susceptibility results are available, antibiotic 
therapy must be de-escalated to avoid emergence of resistance. 
Although no definitive data are reported, recommended 
treatment duration for ABSSSI is at least 7–10 days, but 
according to international guidelines treatment should be 
extended if the clinical condition does not improve [51].
At present, different guidelines have been proposed by 
the national expert panels of different European countries. 
The rationale is to adapt the use of antibiotic therapy to 
the respective national epidemiological situation [34,52–55]. 
On this basis, monotherapy should be attempted if possible. 
Gram-negative coverage is not empirically indicated in most 
cases of ABSSSI; however, clinical risk factors for infections due 
to Gram-negative pathogens should be considered in every 
patient. This point is crucial: early discharge or a switch to 
outpatient therapy, especially in the era of long-acting antibiotics, 
could be delayed by the use of antibiotics for Gram-negative 
TABLE 3. Checklist for early discharge of patients with acute bacterial 
skin and skin-structure infectiona
Discharge checklist Comments
Results of blood cultures and other 
tests
Negative cultures, reduction of 
inflammatory indices, normalizing white 
blood cell count
Evaluation of all co-morbidities No significant alterations of chronic 
diseases, glycaemic control in patients 
with diabetes, no systemic signs of 
infection
Switch to oral therapy or plan for 
outpatient parenteral antibiotic 
therapy
Plan for length of antibiotic therapy after 
discharge, access to day-hospital services, 
ability to take oral medications
Use of long-acting antibiotics In empiric therapy or as early switch to 
these antibiotics
Follow up scheduled Follow up within 7 days from discharge
Education to wound care Correct management of chronic wounds
Continued cares in structures enabled 
or home-care evaluation
Transfer to long-term care facilities or 
evaluation by primary-care physician 
within 48 h from discharge
aAdapted by Amin et al. [69].
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infections. The variability in treatment administration patterns 
and hospital stay observed across countries may be due to 
a number of reasons, including differences in physician and 
patient expectations, and different healthcare systems [56,57]. 
For example, the variability in the rate of intravenous-to-oral 
antibiotic switch may be affected by different perceptions on 
whether oral antibiotics represent the standard of care for 
treating serious infections [58,59]. Oral MRSA-active drugs 
have been implemented in recent algorithms and guidelines 
for treatment of MRSA ABSSSI, further supporting the use of 
these agents [1]. The extent and severity of infections may have 
contributed to a reluctance to switch patients from i.v. to oral 
formulations or to discharge patients sooner.
For ABSSSI due to MRSA, increased hospital length of stay is 
the key cost driver [60]. Therefore, identification of early switch 
and early discharge opportunities for hospitalized patients with 
ABSSSI due to MRSA could lead to a significant reduction in 
length of stay, providing a mechanism for improving outcomes 
and increasing efficacy. Recent data were published on patients 
with MRSA ABSSSI from more than 400 hospitals throughout 
12 European countries [61]: although most patients were 
treated with a targeted intravenous antibiotic therapy, 29% met 
the criteria for an early switch to oral antibiotics and could 
have been discontinued from their intravenous treatment 
roughly 9 days earlier. Moreover, 24% of intravenous-only and 
16% of intravenous-to-oral treatment-switched patients met 
the criteria for early discharge, with a mean potential saving of 
7 days. These data provide useful information on the potential 
for improving current management of these infections.
The new drugs already approved or in development for ABSSSI 
have an important activity against MRSA (see Table 5). Tedizolid 
was reported to be statistically non-inferior to linezolid in 
patients with ABSSSI for an early clinical response evaluated 
48–72 h after the beginning of the therapy [62,63]. Due to their 
long half-life, dalbavancin and oritavancin have the potential to 
be dosed less frequently. Dalbavancin has a prolonged half-life 
of 6–10 days and can be administered with only two doses 
once weekly [64].  The DISCOVER 1 and DISCOVER 2 studies 
showed that once-weekly intravenous dalbavancin was not 
inferior to twice-daily intravenous vanco mycin followed by 
oral linezolid for the treatment of ABSSSI. Adverse events were 
reported less frequently in patients treated with dalbavancin 
than in those treated with vancomycin–linezolid [30]. Of 
interest, Dunne and coworkers recently published a randomized 
clinical trial in which a single 1500 mg infusion of dalbavancin 
was reported as non-inferior to a two-dose regimen with a 
similar safety profile [65], and this single 1500-mg dosage was 
recently approved by European Medicine Agency [66].
Another lipoglycopeptide, oritavancin, is being investigated 
for use in ABSSSI and has the potential to be used as a 
single-dose therapy. The SOLO II trial (Oritavancin Versus 
IV Vancomycin for the Treatment of Patients With ABSSSI) 
evaluated oritavancin efficacy and recently published data 
reported similar efficacy between the single-dose oritavancin 
regimen and twice-daily vancomycin evaluated at early clinical 
and end-of-therapy time points [67].
The new long-acting antibiotics represent a potential 
opportunity for early discharge. These agents make it possible 
TABLE 4. Antimicrobial therapy for skin and soft-tissue infection due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus
Aetiology Antibiotic Dosagea Comments
MSSA Oxacillin 1–2 g every 4 h IV Parenteral drug of choice; inactive against MRSA
Cefazolin 1–2 g every 8 h IV For penicillin-allergic patients
Clindamycin 600 mg every 8 h IV or 300–450 mg qid PO Bacteriostatic; potential of cross-resistance and 
emergence of resistance in erythromycin-resistant strains; 
inducible resistance in MRSA
Doxycycline or minocycline 100 mg bid PO Bacteriostatic
Trimethoprim/sulfamethoxazole One or two double-strength tablets bid PO Bactericidal, recurrent infections
MRSA Tigecycline 100 mg loading dose, followed by 50 mg every 12 h Bacteriostatic, no bacteraemic infections
Teicoplanin 6–10 mg/kg every 12 h for three doses followed by a 
daily dose of 6–10 mg/kg
No data about the new licensed dosage; reported failure 
of therapy; expensive
Vancomycin 30 mg/kg/day in two divided doses IV For penicillin-allergic patients; parenteral drug of choice 
for treatment of infections caused by MRSA
Linezolid 600 mg every 12 h IV or 600 mg bid PO Bacteriostatic
Clindamycin See above See above
Daptomycin 4 mg/kg every 24 h IV Bactericidal
Ceftaroline 600 mg bid IV Bactericidal
Doxycycline or minocycline See above See above
Trimethoprim/sulfamethoxazole See above See above
Abbreviations: SSTI, skin and soft-tissue infection; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; IV, intravenous; qid, four 
times daily; bid, twice daily; PO, by mouth.
aDosage and frequency are based on patients with normal renal function.
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to treat patients with ABSSSI who might otherwise require 
hospitalization on an outpatient basis without compromising 
efficacy. This approach could profoundly modify the manage-
ment of these infections by reducing or in some cases 
eliminating hospitalization costs and risks.
Given the available data, future clinical trials are needed 
to better define the safety and efficacy profile of these new 
antibiotics, especially in sicker patients and for more serious 
infections and to analyse economic aspects. However, the 
characteristics of long-acting antibiotics could represent an 
opportunity for a more targeted management of ABSSSI.
Conclusions
In conclusion,  ABSSSI is a new definition for bacterial infections 
of the skin that includes cellulitis, erysipelas, major skin abscesses 
and wound infection with a considerable extension of skin 
involvement, and that is based upon quantifiable parameters 
such as improvement of the lesion size and of systemic signs of 
infection. Dalbavancin, oritavancin and tedizolid are new drugs 
already approved or in development for ABSSSI. In particular, 
dalbavancin and oritavancin are long-acting antibiotics that 
might create opportunities for early hospital discharge. This 
approach could modify the management of these infections with 
a considerable reduction of hospitalization costs and risks [68].
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